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To	  my	  wonderful	  family	  
"Nobody can go back and start a new begining but 
anyone can start today and make a new ending"
Maria Robinson
ABSTRACT 
Genetic studies of children with mental retardation 
Saideh	  Rajaei 
Department of Medical and Clinical Genetics, Institute of Biomedicine 
The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, 2013 
Mental retardation (MR) is characterised by significant limitations in intellectual function 
and adaptive behaviour. It is estimated that MR affects up to 3% of the population in Europe. 
Patients with MR are an aetiologically heterogeneous group. Approximately 25-35% of the 
patients have a genetic diagnosis. In the last decade, the  introduction of molecular  
karyotyping has proved to add new and important data for MR diagnosis.  
In this thesis, we have undertaken extensive genetic analysis for two groups of children with 
MR. In the first study, a group of fourteen clinically diagnosed early infantile onset Rett 
Syndrome patients were included. The aim for this patient group was to identify  possible 
pathogenic genetic variations. The second study was population-based and included 
children (born 1987–1998; 46 000 children) living in the Swedish County of Halland in 2004. 
133 patients with SMR were identified and then divided in four categories depending on 
timing of onset; prenatal, perinatal, postnatal and undetermined timing. 23 patients within the 
prenatal group (included 82 patients in total), were still undiagnosed. The aims were; firstly to 
investigate whether the aetiological prevalence and co-morbidity of SMR, as well as the 
male: female ratio in  Scandinavia had changed over time. Secondly, to investigate the impact 
of new genetic methodology, like molecular karyotyping, on the number of diagnosed 
children with SMR. 
In the early infantile onset RTT patients we found a MECP2 deletion (1/14) with the initial 
screening, and molecular karyotyping (SNP array) found three (3/14) copy number variations 
with uncertain significance.  
The SMR study showed the same prevalence as previous Scandinavian studies (2.9 per 1000). 
The molecular karyotyping resulted in diagnosis of 5/19 patients of the previously 
undiagnosed patients from the prenatal group, which increased the frequency of diagnosed 
patients from earlier 4% (using traditional analysis methods) to 22.5% (this study). 
Furthermore, we identified MECP2 duplication syndrome in a female patient with mild to 
moderate MR and two brothers from the SMR study. These results imply that MECP2 
duplication is a pathogenic CNV in both genders, thus, there are phenotypic differences in 
females and males. Risk for recurrence is 50% for boys and less for girls because of incomplete 
penetrance.   
In conclusion, this thesis investigates the genetic causes of two specific groups of patients with 
mental retardation. This follow up is essential for prognosis, management, and genetic 
counselling which permit prenatal diagnosis and determination of recurrence risk. 
Key words: Mental retardation, Rett syndrome, RTT, early onset infantile RTT, MECP2, SMR, SNP array, copy 
number variations, CNV, MECP2 duplication syndrome 
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___________________________________________________________________________ 
INTRODUCTION 
Basic Genetics 
All living organisms, from prokaryotic microorganisms such as bacteria to multi-cellular 
eukaryotic organisms; animals and plants, carry their instruction for how to develop and 
function in the Deoxyribonucleic acid (DNA) molecules. The inherited information for each 
organism is coded by its DNA, and the DNA is located in the nucleus in the eukaryotic cells. 
The DNA is composed of a double-stranded polymer and  consists of combination of four 
bases (nucleotides); adenine (A), guanine (G), cytosine (C) and thymine (T). In each strand, 
the nucleotides are linked together by covalent phosphodiester bonds that join the 5´ carbon 
of one deoxyribose group to the 3´ carbon of the next. The two DNA strands form a double 
helix by the complementary hydrogen bonds between A-T and G-C base pairs. The DNA 
double helix was first described by  Watson and Crick in 1953.1
DNA and Genes 
According to the official guideline for Human Gene Nomenclature (HGNC), a gene is 
defined as: "A DNA segment that contributes to phenotype/function. In the absence of 
demonstrated function a gene may be characterized by sequence, transcription or 
homology".  
Genes are spaced at irregular intervals along the DNA sequence and take up only 1-2% of 
the genome; the complete human genome sequence has been estimated to contain 
approximately 26,000-40,000 genes, by recent publications supported by the International  
Human Genome Sequencing Consortium.2,3 The remaining DNA encodes for non-
translated RNA or constitutes regulatory sequences, introns, repetitive sequences, 
pseudogenes and most regions have unknown function, at least at present. The classical  
view of a gene structure is that it is composed of exons and introns. Besides exons and 
introns, a crucial regulatory element is the promoter, which is a short DNA sequence placed 
upstream (5´) of the gene. The promoter is recognized by transcription factors which 
initiate the transcription. The exons are the segments that contribute genetic information to 
the final product by coding for amino acids which build up the protein. 
Exons are separated by introns which are noncoding segments that are processed through 
RNA splicing, which removes intronic RNA segment during transcription. RNA splicing 
requires recognition of the intronic and exonic sequences (Figure 1). The
dinucleotides at the ends of introns are highly conserved, and as a rule the introns start  
with a GT and end with AG (the GT-AG rule).  
The exons consist of triplets, called codons which are translated to proteins by use of the 
“universal” genetic codes. Also, the transcription always begins at a specific start codon 
“ATG” and finishes with stop codons “TAA, TAG and TGA” (Figure 1). 
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Figure 1 Schematic figure of the process from gene to protein. The gene is transcribed to primary RNA, 
which is a continuous RNA copy of the gene with both exons and introns. The primary 
transcript is then cleaved at the exon-intron bounderis. The intronic sequences are snippeded out
and discarded in the premature mRNA. The maturation of mRNA is complete when the exonic
seqences are fused together (spliced) in the same linear order as in the gene. Finally, the mRNA 
is used as a template for protein which actually carries out the function.  
The central dogma of molecular biology
The hybridization of DNA and RNA allows for accurate copying of the genetic material
either prior to cell division (replication) or for the production of RNA (transcription) and
protein (translation) from specific genes in the DNA (Figure 2). The replication has a  
semi-conservative approach; the two strands of DNA separate and new strands are
synthesized onto the existing strands. The resulting DNA molecules are hybrids of new
and old DNA.1,4 Genetic information generally flows in a one-way direction in the sequence:
DNA is decoded to make RNA, and then RNA is used to make polypeptides that are
subsequently forms of protein. This flow of genetic information has been described as the
central dogma of molecular biology, because it is universal among most of living
organisms (Figure 2).
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Figure 2 The central dogma. The cell division begins with DNA replication when the DNA polymerase 
in a semi-conservative approach makes two DNA double strands the old DNA strand as a 
template.The process of genetic information is essential in two steps: 1) transcription, which 
happens in the nucleus (in the eukaryotic cells), where DNA is used as a template for RNA 
synthesizing by RNA polymerase enzymes. 2) Translation, which takes place in ribosomes in 
the cytoplasm, where the mRNA are decoded to polypeptides. 
Human Genetics	  The human genome consists of more than 3 billion base pairs (bp), as the cells enter mitosis 
the chromatin condenses to chromosomes.5 The entire genome is then organized in 23 
chromosome pairs, in which 22 pairs are autosomes and one pair, consist of the sex 
chromosomes; X and Y (Figure 3A). There are two copies of each autosome 
(chromosomes 1-22) in both females and males. The sex chromosomes are different;  there 
are two copies of the X chromosome in females, but males have a single X chromosome 
paired with a Y chromosome. Chromosomes are generally numbered in order of decreasing 
size; the largest chromosome is 1, followed by chromosome 2 and 3 etc. The sex 
chromosomes X and Y and also chromosome 21 which is smaller than chromosome 22 are 
the exception to this rule (Figure 3A). 
The short arm of each chromosome is denoted p and the long arm q. The specific 
chromosomal locations have traditionally been referred to the banding pattern obtained  by 
Trypsin/Giesma staining of mitotic chromosomes (Figure 3B) (ISCN; International Standing 
committee on human cytogentic nomenclature 1995) according to this system the 
chromosomal bands are numbered from the centromere and outwards along the 
chromosome arms. Recently, the principle has changed to some extent and the position of a 
particular gene is now commonly given in mega bases (Mb), as calculated distance from the 
p-terminal of the chromosome.
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Figure 3 A) A Human normal male karyotype showing 46 chromosomes, 23 pairs. Karyotype kindly provided
 by Ylva Sirenius, Department of Clinical Genetics, SU/Sahlgrenska. B) Schematic picture of the X
 chromosome, displaying the banding pattern obtained by Trypsin/Giesma staining (NCBI).  
Genetic variation and diseases 
Generally, there are two main types of aberrations to be assayed for genetic diseases and 
disorders: 
1. Small scale alteration at DNA level such as basepair substitutions (also refferd to as point
mutations), and small insertions and deletions in specific genes. These variations often affect 
the gene product; the protein. The greatest source of mutations is spontaneous errors in DNA 
replication and repair (Strachan & Reed 4th edition).6 New mutations arise in the somatic cells 
or in the germline of an individual. Germline mutations can be pathogenic (disease causing) 
and are inheritable, which means that they can be transmitted to offspring  of the individual. 
In contrast, most somatic mutations are neither inheritable nor pathogenic since only single 
cellclones are affected (with exceptions in cancer). On the other hand, it is common that more 
than one nucleotide can localize at the same genomic position in the population, this 
phenomenon is called single nucleotide polymorphisms or SNPs. However, about one 
nucleotide of 300 is polymorphic. These SNPs are catalogued in the public dbSNP database; 
(hTTP://www.ncbi.nlm.nih.gov/projects/SNP). 
14
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2. Large scale aberration at a chromosomal level; chromosomal abnormalities are
classified in two types: Constitutional abnormalities which occur very early in 
development (abnormality in sperm or egg and maybe abnormal event in the very early 
embryo) resulting in presence of the aberration in all cells of body. The abnormality is 
somatic if it is only present in clones of cells or specific tissues. An individual with a 
somatic abnormality is called to be mosaic when there are two populations of cells with 
different chromosomal constitution; both derived from the same zygote. 
Chromosomal alterations, whether constitutional or somatic, are mostly divided in two 
categories; A) Numerical abnormalities as trisomy; three copies  of a chromosome  instead 
 of two copies (for example trisomy 21 in Down syndrome; e.g. 47,XX,21)  or monosomy, 
when one of the chromosomes is missing (for example monosomy X in Turner syndrome; 
45,X). B) Structural abnormalities such as translocations, or gains and losses. These types 
of aberrations, with the exception of balanced translocations, can also cause copy number 
variation (CNV) in the affected chromosomal regions and can be identified using a variety 
of cytogenetic methods or copy number assays (see also page 21).
Genetic aberrations include “epigentic” mechanisms which may affect the phenotype in 
genetic diseases. Epigenetics is commonly defined as a mitotic and/or meiotic heritable 
change of gene expression caused by other mechanisms than variations in the underlying 
DNA sequence. DNA methylation and histone modification are the most common 
epigenetic mechanisms that affect gene expression. The most common epigenetic change is
the X chromosome inactivation in females.6
Mendelian inheritance 
Monogenic inherited traits are caused by single locus variations in the genome, which are 
transmitted through Mendeline inheritance. Named after the father of modern genetics; 
George Mendel who in the 1860 grounded the principle of inheritance pattern. The 
monogenic inheritance is called dominant if only one allele of two possible alleles in the 
locus leads to demonstration of a certain phenotype. But the inheritance is recessive if 
demonstration of the phenotype is depending on the presence of the same alleles in both 
positions in the locus. Nowadays, many thousands of Mendelian traits or diseases are 
known and information about them have been catalogued in the OMIM (Online Mendelian 
Inheritance in Man) database; (http://www.omim.org/). 
X chromosome inactivation 
The human X chromosome carries many essential genes expressed during the 
development. In contrast, the Y chromosome in males carries very few genes; which are 
mainly related to male sexual functions. It means that females have twice as many of the 
X chromosomes genes as males. X chromosome inactivation (XCI) is the modulator for 
this excess of genes in females. Due to XCI one of the two X chromosomes in all cells in 
women undergo inactivation. It is a random process which occurs early in embryogenesis 
(probably in the 10-20 cell stage), in each cell independent to other  cells.6 The XCI is  
irreversible during lifetime of the cell and the particular inactivated X chromosome 
remains inactivated in all its daughter cells. Thus, all females are mosaics of clones in 
which different X chromosomes (either paternal or maternal inherited X) are expressed. 
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 Inactivation is usually random which means that one of the X chromosomes is 
inactivated in 50% of a female’s cells and the other X chromosome is inactivated in the 
remaining cells. X chromosome inactivation is considered as skewed in some conditions 
if the ratio of active to inactive X is less or equal to 75:25.7 
This process may explain why female carriers of recessive X-linked conditions (as the  
MECP2 duplication syndrome in this thesis) only display minor signs of the phenotype, 
and also why females, heterozygous for a dominant  X-linked condition, usually show  
milder and  more  variable  phenotype  than  males with  the  same  X-linked  
condition. 
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BACKGROUND 
Mental Retardation 
Mental retardation (MR) is characterised by significant limitations in intellectual function 
and adaptive behaviour. It is estimated that MR affects up to 3% of the European population.8 
MR is one of the most important unsolved clinical determinants in healthcare.8 The ability of 
cognitive functions is commonly determined by the definition of the Intelligence Quotient 
(IQ). Assuming a population mean IQ of 100, MR can be subdivided into four degrees of 
severity: mild (IQ 50–55 to approximately 69), moderate (IQ 35–40 to 50–55), severe (IQ 20–
25 to 35–40), and profound (IQ below 20-25)according to  World Health Organization 
(TheICD-10 classification of mental and behavioral disorders.WHO: 2001).
The diagnosis of MR is established based on three following criteria:8
1. Onset of MR symptoms before 18 years of age.
2. Intellectual functions significantly lower than average ( IQ < 70).
3. Poor adaptive skills in at least two of the following areas: communication, self-care,
social/interpersonal skills, self-guidance, school performance, work, leisure,
health, and safety.
MR is exceptionally heterogeneous and complex in its aetiology, which is predominantly 
genetic but can also be environmental (for example fetal alcohol syndrome). Environmental 
factors such as perinatal hypoxia or infection and teratogenic agents (such as viruses or
chemicals that cross the placenta during pregnancy), as well as genetic variations such as 
chromosomal aberrations, known microdeletion/microduplication syndromes and point 
mutations in specific gens, all have been implicated to cause MR and dysmorphology. 
Genetics of MR 
It is estimated that 25–35% of patients with mental retardation might have a genetic 
background.8 A search of MR in the online Mendelian Inheritance in Man database (OMIM) 
has a score of 2726 hit of known genetic condition. Many of these are chromosomal 
syndromic disorders such as Down’s syndrome (trisomy 21) and rare syndromes which 
result from submicroscopic deletions (like 22q11 deletion syndrome) or duplications. These 
conditions are usually associated with specific congenital abnormalities and  
dysmorphology.9  There are also some syndromic disorders which have known and well 
described inclusion criteria, and are associated to pathogenic variations in one or several 
known gene/genes, such as Rett syndrome (associated with the MECP2 gene). 
On the other hand, there is a group of non-syndromic MR patients  who have no specific 
symptoms, dysmorphology or other congenital features which enable a clinical diagnosis. 
Although there are state-of-the-art strategies implicated in the genetic testing of MR patients, 
the majority of these patients still lack aetiological diagnosis.10 
X-linked mental retardation 
The estimated male:female ratio is ranging from 1.3:1–1.8:1,8,11-14 and the over all male 
dominance for mental retardation has been well described in several studies. The prevalence 
of MR in males, up to 30% higher than for females, may be explained by the large amount  
 of X-Linked mental retardation (XLMR) genes reported in literature. 
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 More than 200 conditions and defects and 109 XLMR genes are listed on the website of 
XLID (Greenwood Genetic center, http://www.ggc.org/research/moleculargstudies/
xlid.html, updated November 2012).  The inheritance pattern of X linked genes in males is 
different from inheritance of genes located on the autosomes, since there is just one allele for 
each gene on the X chromosomes. Intellectual disabilities, predominantly affecting males, are 
commonly due to pathogenic variations in XLMR genes, which probably are partly 
responsible for the higher prevalence of MR among males compared to females.15,16 An 
example is the MECP2 duplication syndrome which affects male patients very severely but 
the same syndrome has variable expressivity in females, from asymptomatic to mild or  
moderate mental retardation.7  Accordingly, some X-linked conditions are not compatible 
with life for males. An example is Rett syndrome (RTT) which almost exclusively affects only 
females. However a few male patients with MECP2 mutation have been reported. The male 
phenotype range from sever congenital encephalopathy, mild MR and various 
neurological symptoms.17,18 
 Rett Syndrome 
History 
Rett Syndrome (RTT) is named after Andreas Rett, an Austrian paediatric neurologist, who 
first recognised the characteristic features of the syndrome. In 1966, Rett described similar 
findings in 22 patients, for the first time as a unique clinical entity [Rett,1966, in German]. 
Meanwhile, in 1960, young female patients in Sweden with quite similar symptoms were 
observed by Bengt Hagberg. RTT became recognized in the medical community in 1983, 
when Hagberg and his colleagues reported 35 cases of RTT (from Sweden, France and 
Portugal) in the English language.19 RTT with an incidence of 1:10 000 females, is now 
recognised worldwide as one of the most common causes of mental retardation in girls.20
Clinical features of Rett Syndrome 
Rett syndrome diagnosis is based on several characteristic clinical criteria.21 RTT (MIM 
312750) is a postnatal progressive neurodevlopmental disorder characterised by normal 
development up to the age of 6-18 months. Then the development stagnates, this is followed 
by rapid deterioration of motor development, autistic behavior, loss of purposeful use of the 
hands, jerky truncal ataxia, microcephaly and epilepsy.19,20,22,23 Rett syndrome is clinically 
divided to two subgroups: 
1) Classical Rett syndrome, which is the most typical form of Rett Syndrome (80-90% of
RTT diagnosed patients).18 The development of classical RTT is divided in four stages:24 
Stage I) Early onset stagnation: which arise after 6-18 month of normal development, 
when the girls almost stop to acquire new skills, head growth decelerates with onset of 
autistic behavior.
Stage II) Rapid developmental regression (onset age 1-4 year) with loss of previously 
acquired skills. 
Stage III) Pseudo stationary period (onset age 4-7 years), in this stage most girls regain 
some of activities and improve eye contact.
Stage IV) Late motor deterioration (in the following 10-12 years), lower motor neurons 
impairment becomes prominent resulting in that the most adult RTT patients  are restricted 
to wheelchairs. They are severely mental retarded and develop scoliosis.
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2) Variant Rett syndrome, deviates from the typical form in different aspects: there are
several atypical types of RTT, some are milder as forme furstes (FF), preserved speech 
variant (PSV) and late regression24,25 and some are more severe as congenital and early onset 
infantile variants. 24,26 Beside of RTT variant girls, there are male patients with RTT-like 
features which attracting an increasing research interest.  
Genetic basis of Rett syndrome 
In  parallel  with  the  worldwide  recognition  of  RTT  in  the  1980s,  For  the  first  time,  a  
connection  was  established  between  DNA  methylation  and  heritable  effects  of  gene 
expression.27 Identification of the site of almost all DNA methylation in mammalian 
genomes as the dinucleotide 5´-CG-3´ (known as CpG), was the beginning of  exploration of 
the effects of this modification on gene activity. Two mechanisms have been suggested for 
methylation-mediated gene repression. The first suggests that  methylation of CpG sites 
(called CpG islands) within gene promoters will inhibit sequence-specific binding of 
transcription factors. In the second, more prevalent  mechanism, the repression is mediated 
by proteins which specifically bind to methylated CpGs (methyl-CpG binding proteins) and 
thereby alter the chromatin structure, rendering it inaccessible to the transcription 
machinery.28 In 1992, Adrian Bird and coworkers identified a novel mammalian protein that 
binds methylated CpGs, methyl-CpG binding protein 2(MeCP2).28
The gene behind RTT was identified in  1999, by Amir et al. They reported the first cases of 
RTT patients with mutations in the MECP2 gene located on chromosome Xq28.29 They 
suggested the abnormal epigenetic regulation as the underlying mechanism for the 
pathogenesis of RTT.29 However, pathogenic variations in MECP2 are identified in more 
than 95% of classical RTT cases.  The variations include missense, nonsense, and frameshift 
mutations, which mostly are de novo of paternal orignin and often involve a C to T transition 
at CpG dinucleotides. 18,30,31 Detection of larger deletions in MECP2 became possible when 
the MLPA method was introduced in the MECP2 analysis.32 The most common deleterious 
variations (refered to as “hotspot” mutations in the MECP2 gene) as well as gross deletions 
(including one or several exons) are presented in the RettBASE: IRSF MECP2 Variation 
Database (http://mecp2.chw.edu.au/), together with phenotype-genotype correlations.  
In this thesis, we have focused on genetic analysis of the “early infantile onset RTT 
variant” (paper I and III). This variant may be more severe and the disease debut is in very 
early infancy; before 6 month of age. At older age, the symptoms appear more and more like 
the classical RTT (Table 1). However, pathogenic variants in MECP2 are rarely identified in 
RTT variants.33 
Other candidate genes have been suggested to be relevant for some of the RTT variants, like 
congenital RTT variant, namely the Cycling Dependent Kinase-Like 5, (CDKL5) gene located 
at Xp22 and the Fork head box G1 (FOXG1) gene located at 14q12.  
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Early infantile onset Rett Syndrome variant
Table 1 Early onset infantile Rett syndrome variant clinical criteria1 
Primary	  criteria,	  >	  3	  required	   Supportive	  criteria,	  	  >	  5	  required	  
-Loss	  of	  acquired	  fine	  finger	  skill	  or	  never	  present 
-Loss	  of	  learned	  single	  words/phrase	  
-RTT	  hand	  stereotypies,	  hands	  together	  or	  apart 
-Early	  deviant	  disturbed	  communicative	  ability
-Deceleration	  of	  head	  growth	  
-The	  RTT	  disease	  profile:	  	  
a	  regression	  period	  (stage	  II)	  	  
followed	  by	  a	  come	  back	  (stage	  III)	  	  
contrasting	  to	  slow	  neuromotor	  regression 
	  -Breath	  irregularities	  (hyperventilation	  and/or	  breathholding) 
-Bloating/marked	  air	  swallowing	  
-Characteristic	  RTT	  teeth	  grinding,	  Gait	  dyspraxia/apraxia	  
-Neurogenic	  scoliosis	  (high	  kyphosis,	  ambulant)	  
-Appearing	  abnormal	  lower	  limb	  neurology	  
-Small	  blue/cold	  feet	  
-Unmotivated	  sudden	  laughing/screaming	  spells	  
-Impaired/delayed	  nociception	  indicated	  
-The	  RTT	  characteristi	  eye	  pointing	  
NOTE:	  RTT=	  Rett	  syndrome	  	  
1Unpublished	  data	  from	  paperI	  
MECP2; one gene, several diseases 
The human MECP2 gene consists of four exons resulting in expression of two protein isoforms 
due to alternative splicing of exon 2. The splice variants differ only in their N-terminus, and 
include the more abundant MeCP2-e1 isoform (encoded by MECP2B) as well as the 
MeCP2-e2 isoform (encoded by MECP2A).34 Since recognition of a causative  relationship 
between MECP2 and RTT, many research laboratories have tried to find out the key molecular 
signaling pathway of MECP2 and its expression pattern using different genetic mouse models. 
The impressive large amount of different types of the MECP2 manipulated mouse models; 
including Mecp2 null mice, models with various defected (mutated) Mecp2 and also mouse 
models with over expressed Mecp2, have contributed to the knowledge about MECP2 today.  
In brief, using genetic mouse models, key molecular signaling pathways that contribute to the 
deficits in synaptic function, the numbers of synapses and dendrites as well as maturation of 
neurons have been observed.35-39 Once identified, these mouse models have also been used to 
experimentally validate possible therapeutic avenues using genetics, pharmacological, and 
behavioral approaches.40  However, the results of these studies suggest the MeCP2 protein 
function as a genome-wide modulator with global  effect on many other genes.40-42  The 
MeCP2 protein is an important member in a complex cascade of reactions that regulates other 
genes as BDNF, IGF and Dlx5/6 by interaction with other factors as Sin 3-histone deacetylase 
complex and other coactivators. 43,44 Interestingly, recent results suggest that MeCP2-e2 
isoform is upregulated in Aβ-treated cortical neurons and promotes neuronal death in post-  
mitotic neurons, a pathway normally inhibited by fork head protein FOXG1.45  This finding 
may explain the role of pathogenic variants in FOXG1 which have been reported in congenital 
RTT variants.46-49  
Furthermore, MECP2 mutations have been reported in patients with diagnosises different from 
RTT: Autism (1-2%, mostly in the C terminal of gene), mild MR,  Angelman syndrome-like 
(which has overlapping criteria with early infantile onset  RTT) and also juvenile onset 
schizophrenia.  
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The dosage of MeCP2 has phenotypic impact as well, a mouse model with over-expression 
of a trans-gene containing the human MECP2 gene, that showed a near twofold MeCP2 
expression, demonstrated severe progressive neurological effects.50 The effect of MECP2 
over-expression has also been observed in human, where a double dosage of MECP2 causes 
severe developmental delay and mental retardation.51-54 
MECP2 duplication syndrome 
In 1999, Lubs et al. presented a family with severe XLMR, hypotonia and a mild 
myopathy.51Three of the five affected males in this family died of secondary complications 
before the age of 10 years and none have survived past the age of 10. These complications 
included swallowing dysfunction and gastroesophageal reflux with secondary recurrent 
respiratory infections. He also described specific characteristic features in this group, 
including downslanting palpebral fissures, hypertelorism, and short nose with a low nasal 
bridge.51 Interestingly, three obligate carriers in Lubs study had an IQ less than 80. The
suggested localization for the causal gene was distal to  DXS8103 in Xq28.51 Along with the 
progress of molecular genetic technologies, several male cases of Xq28 duplications 
including MECP2 have been detected (by for example microarray).52-54 The duplicated 
regions differ in size and are usually inherited from unaffected mothers. 
Genotype-phenotype correlation studies suggest that the minimal duplicated region required 
for the syndromic specific phenotype in males include the entire MECP2 coding sequence 
and the adjacent IRAK1 gene (see also figure1, paper IV). The MECP2 gene has been 
suggested to be the dosage sensitive gene that mediate neurological outcome.53,55 The 
prevalence of MECP2 duplication syndrome (OMIM 300260) is estimated to 1% of patients 
with unexplained XLMR56-58, and 2% of male patients with severe encephalopathy.59
The clinical manifestation in male patients is now updated and includes a variety of 
moderate to severe mental retardation, hypotonia, delayed or absent speech, epilepsy, late 
onset spasticity as well as feeding difficulties and recurrent respiratory infections.60-62 
Nevertheless, female carriers with almost completely skewed XCI in peripheral blood have 
been considered as asymptomatic.61,63,64 Later on, affected  females with X:autosome  
translocation resulting in MECP2 duplication have been reported.65 Eventually, other cases 
of females with de novo MECP2 duplications were observed.66-68 The phenotype in females 
differs from the male phenotype, in females it is broad and ranges from asymptomatic to 
moderate MR, with learning disabilities, anxiety, slightly dysmorphism and autistic features. 
The minimal  duplicated region required for appearance of phenotype is smaller in females 
compared to males and includes only MECP2 (paper IV).66-68 
However, further studies of this syndrome are needed to clarify  the inclusion criteria, 
especially in females. In female cases other factors as X chromosome inactivation and 
incomplete penetrance may also be important phenotypic modifiers.  
Microdeletion and microduplication syndromes 
Genotype, phenotype, penetrance and variable expression 
As discussed earlier in chromosomal aberrations (see Page 15), all individuals carry copy 
number variations (CNVs), also refered to as microdeletions or microduplications, in the 
genome (refers to genotype). Most common CNVs are normal variations. The effect on the 
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phenotype depends on several factors; for example the size of the variation, the gene content, 
or other functional elements located in the region of interest. International guidelines for 
interpretation of CNVs have been published by Miller et al., 2010.69 SNP microarrays and 
DNA sequencing technologies have increased the resolution, thus made it far easier to identify 
smaller CNVs. Some well known variants can cause very specific phenotypes, as most 
microdeletion syndromes, while others, often microduplication syndromes, may be associated 
to variable expressivity.70 Only genes which are dosage dependent are influence the phenotype 
(for example haploinsufficient genes). 
The probability to display a specific phenotype due to a genetic variation is what is usually 
referred to as the penetrance. On the other hand, variable expressivity has been described for 
many syndromes such as 22q11 duplication syndrome, 16q11 duplication syndrome etc. These 
syndromes present with very broad phenotypic spectra, which even include carriers with very 
mild symptoms, which are difficult to identify in a clinical setting. It is not unusual that the 
carriers with mild symptoms only are identified after the diagnosis has been established for a 
family member with more evident symptoms. 
An example is the 22q11.2 deletion that causes a multi-systemic disorder, the 22q11.2  deletion 
syndrome (also known as velocardiofacial syndrome or DiGeorge syndrome). Approximately 
93 % of the patients have a de novo deletion, and 7 % have inherited the deletion from a parent, 
sometimes mildly affected. Many patients with the deletion have learning disorder, congenital 
heart defects, malformed palate, mild facial abnormalities, neuropsychiatric illness, and 
sensitivity to infections.71 The phenotype is variable and may include facial dysmorphism, 
cardiovascular abnormalities, short stature, cognitive and behavioural impairments and a high 
risk of schizophrenia.71,72 Causative genes in the 22q11.2 region include COMT (catechol-O-
methyltransferase isoform MB- COMT)73  and T box1; TBX1 gene.74 
Duplication of 22q11.2 also has variable clinical presentation, including developmental delay, 
dysmorphic facial features, autism, and cognitive and behavioural impairments75, but here the 
ratio of inherited duplications is almost 70 %. The duplication syndrome has incomplete 
penetrance, and a parent who has 22q11.2 duplication can have a normal or near-normal 
phenotype. Because of incomplete penetrance both parents  need to be tested to distinguish 
from de novo cases.    
In conclusion, interpretation of CNVs is an important stage in diagnostic genetics. Access to 
the phenotype and liable and strong evidence for correlation between the genotype of interest 
is crucial. To date, many useful tools have been provided by different international  
communities with genetic expertise to enable the interpretation. However, there are still 
variants which are difficult to interpret as data may be inconclusive or missing.  
The Database of Genomic Variants (DGV) from Centre for Applied Genomics ; 
(http://projects.tcag.ca/variation), is the platform where many of the normal variants from the 
populations and the frequency of them have been collected together. DECIPHER database 
(DatabasE of Chromosome Imbalance and Phenotype in Humans using Ensembl Resources; 
https://decipher.sanger.ac.uk) from Welcome Trust Sanger Institute, is another databases that 
is essential for comparison of detected variations with reported patients.  DECIPHER  is also a 
phenotypic database, it is a comprehensive database which incorporates data from several
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databases, the information includes, reported variations together with related 
phenotype, common copy-number changes in healthy  populations are also displayed 
and genes of recognized clinical importance are highlighted. These databases and also 
searching in OMIM (Online Mendelian Inheritance in Man) home pages and PubMed 
(the U.S. National Library of Medicine; http://www.ncbi.nlm.nih.gov/), are essential 
for medical validation. 
Other databases as Unique database (http://www.rarechromo.co.uk/) are available with 
description of both old and new microdeletion/microduplication syndromes and the 
related criteria. 
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MATERIALS AND METHODS 
Patients and controls 
In this thesis, we have studied two groups of patients with genetic analysis. The first 
group consists of 14 patients with early infantile onset Rett Syndrome variant which have 
resulted in paper I and III. The patients in this study with early infantile onset 
RTT variant phenotypes (young girls as well as adult women) have been examined and 
collected over 40 years by professor emeritus Bengt Hagberg. Most of the women have 
been systematically examined and diagnosed according to the previously published 
clinical diagnostic programme.25  
The other group consists of 133 patients with severe mental retardation (SMR), 
these children have been epidemiologically collected and categorised in different 
categories. Twenty-three patients in this group were categorised in “the prenatal unknown  
aetiology” subgroup. We have analysed 19/23 of these patients with microarray technique 
in paper II. Two brothers in this group had the same maternally inherited X-linked 
aberration; the brothers have been further studied and compared with a female patient 
with a partly overlapping genetic aberration in paper IV. 
In addition, a reference set of 45 in-house controls with common CNVs in the Western  
Swedish population was used to exclude common benign CNVs in paper II-IV.
In paper I we have studied 14 cases with early infantile onset variant of Rett syndrome. The 
women’s phenotypes were collected from medical history and examination of the patients. 
For inclusion the patients had to have shown definitely abnormal signs or deviant 
developmental profiles before the age of six months. All fulfilled three or more Rett variant 
criteria and five or more supportive criteria.22 Four had documented epilepsy, five had no 
seizures and five had missing information on seizures.  
12 patients from study I remained without causative genetic aberration, in paper III we have 
further studied these 12 patients for copy number variations.  
Paper II and IV 
In paper II, children with SMR in the Swedish county of Halland area were investigated. 
133 children with SMR between 6-17 years old, born in 1987-1998 living in the county at 
December 31st, 2004 and registered at the habilitation centres, paediatric clinic and school 
health services were identified. The children were examined with CT, MRI, metabolic 
screening, karyotyping and further genetic analyses when indicated at the clinical 
examination. Classification of aetiologies was made similar to those used in previous 
Scandinavian studies.12,13,76 Patients were categorised in 4 main aetiologies; prenatal in 82 
(62 %), perinatal in 14 (10 %) and postnatal in 8 (6%) children in relationship of birth 
time. In 29 children (22 %) it was not possible to relate the condition to the time of birth, 
and was categorised as undetermined timing, 24 of these children were males with autistic 
disorders. Each category was then divided in sub group according to the diagnosis of SMR. 
The prenatal aetiology is divided to genetic, acquired and unknown aetiology subgroups. 
The prenatal genetic group were based on the results of the clinical observations as well as 
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Paper I and III
genetic analysis and includes 57 patients in which 34 with chromosomal abnormalities 
such as Down syndrome and 6 patients diagnosed with other known chromosomal 
aberration detected with traditional karyotyping; (marker chromosome 15q, partial 
trisomy 11, partial monosomy 2q, mosaic trisomy 8, Pallister-Killian syndrome  and  
deletion 3p).  
The other group  encompasses 14 patients with monogenic or presumed monogenic 
disorders: (tuberous sclerosis, Angelman syndrome, Cornelia deLange syndrome, 
Laurence-Moon-Biedl, infantile neuroaxonal dystrophy and Rett syndrome). Three girls 
were diagnosed with metabolic disorders and five cases had malformation syndromes as 
diagnosis. The Acquired group comprised two children, both with spastic tetraplegic. 
Microarray analysis was implicated for propose of determination of aetiology in 23 
children with unknown prenatal aetiology, and 19/23 patients were subsequently analysed 
by microarray in the paper II; (for 4 patients in this group, blood samples were not 
available).  In paper IV, we have analysed a female patient with mild to moderate mental 
retardation who had a duplication at chromosome band Xq28, which the two brothers in 
paper II also shared and we have here described the female phenotype in comparison to 
male phenotype. 
Molecular Genetic Methods 
In order to detect small scale genetic aberration in patients in this thesis, we have used 
three polymerase chain reactions (PCR) based methods in paper I and III. PCR is an 
in vitro method for amplification of DNA sequences using oligonucleotide primers.	  
DNA sequencing 
DNA sequencing (developed first by Fredrick Sanger, 1977) is the most widely-used  
analysis method to analyze the base composition of stretches of DNA. We used 
terminator chemistry DNA sequencing in paper I and III. In order to ensure high quality 
of sequencing results, the PCR products were purified with for example enzymes or spin 
columns. Then, the purified PCR products were added to the sequencing reaction, which 
requires a mix consisting of buffers, dNTP:s, ddNTP:s, sequencing primers (one primer 
at a time, either forward primer (5´→3´) or reverse primer (3´→5´)) and enzyme for 
elongation of the sequencing product. The ddNTP:s (A, C, G or T) are labeled with a 
fluorescent molecule which results in one specific color for each one of them. The labeled 
ddNTP:s were also modified without a hydroxyl group on the 3´carbon which interrupts 
the elongation procedure. As both dNTP:s and ddNTP:s were randomly involved in the 
sequencing process, it results in all possible lengths of sequence products separated by 
one base in the final mixture. These products were separated according to the product 
length through electrophoresis, the negatively charged DNA fragments migrate to the 
positive anode in the electric field and the camera recognized the different florescence 
dyes and the software processed the results into electropherograms. In this work we used  
the ABI 3100 instrument (Applied Biosystems) and the Seq Scape collection program 
(Applied Biosystems) to final analysis of obtained DNA sequences. 
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Mutation detection methods 
Denaturing High Performance Liquid Chromatography (DHPLC) 
In summary, DHPLC is a mutation screening method based on liquid chromatography for 
detection of heteroduplexes in PCR amplified fragments. We applied this method in paper I 
for analysis of CDKL5 gene. Melting profiles and DHPLC run conditions can be determined 
by Navigator Software (Transgenomic). PCR products are denatured and slowly renatured, 
which create perfectly matching homoduplexes (wild type) and heteroduplexes (mismatched 
bp due to mutation), the hetroduplexes have lower melting temperature than homoduplexes 
which results in different peak-patterns from wild-type to mutant in the chromatogram.
Multiplex Ligation-depended Probe Amplification (MLPA) 
MLPA is a multiplex PCR method which can be used for the relative quantification of DNA 
(or RNA).77 It can be used to detect moderate to large insertions, deletions, duplications and 
copy number variations in targeted genes or regions. The MLPA reactions comprises of  5 
steps: 1) Denaturation of DNA and hybridization of specific unique MLPA probes (each 
probe is designed in two parts). 2) Ligation using Ligase enzyme to fill the gap between the 
two parts of each hybridized probe. 3) Multiplex PCR reaction using universal  primers 
which amplifies all amplicons in one reaction. 4) Separation of amplification products 
according to their unique length in each MLPA kit by electrophoresis. 5) Data analysis. 
We used the Gene Scan Analysis Software v3.7 (Applied Biosystems) and the Sequence Pilot 
version 1.2 software (JSI medical system). The MECP2 MLPA kit P015 from MRC Hollad 
was used in paper I to detect deletion in MECP2 and also to verify the result of MECP2 
duplication syndrome in paper IV. In addition MLPA was used to verify some of our 
findings in paper II (22q11 deletion). 
SNP array
Single nucleotide polymorphisms (SNPs) are the most common source of genetic variation 
in the human genome, and refer to genomic positions where two or more bases are found 
in populations. The frequency of about 10 million, evenly dispersed across the genome, 
makes SNPs a suitable marker to copy number analysis.78 Early studies with chromosomal 
karyotyping (with low resolution) and fluorescent in situ hybridization (FISH) were limited 
in their ability to detect only the largest CNVs due to large probes, but increased resolution 
of SNP microarrays have made smaller CNVs far easier to identify.70 
In paper II-IV, we have used Affymetrix Genome-Wide Human SNP 6.0 Array and 
Affymetrix cytogentic Whole Genome 2.7M array to investigate and identify CNVs in our 
patients. Affymetrix GeneChipTM technology applies a combination of photolithography 
and combinatorial chemistry with light- directed in situ synthesis oligonucleotides on a 
glass surface. The Genome-wide Human SNP Array 6.0, has 1.8 million markers which are 
25 bases long oligonucleotides probes with 1-5 kb median marker spacing and consist of 
SNP probes (906,600 in SNP 6.0 array) and  Copy number probes (CNP; 946,000 probes in 
SNP 6.0). 
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 We used Affymetrix cytogenetic Whole Genome 2.7M array in paper II which provides 
whole genome coverage with a high density of 2.7 million oligonuclotide markers, of which 
400 103 are SNP probes. The principle of the SNP array method is shown in Figure 4. 
Data from Genome Wide Human SNP 6.0 Array was analysed with theAffymetrix  
Genotyping Consol v2.1 software and then Affymetrix Chromosome Analysis Suite 
(ChAS) 1.0.1 software and the NetAffx build 32 was used to visualise the patient’s copy 
number variation. ChAS Software is designed for cytogenetic researchers. The provided 
in-silico controls in the software and also in-house controls can be used to excludes  the 
most common CNVs in population. In additions, there is direct linking to useful databases 
as OMIM, DVG and UCSC integrated in the software that allows researchers to compare 
and interpret the region of interest with these databases.
Figure 4 The SNP array reactions step by step are as follows; 1) Digestion of 250 ng of genomic DNA 
with each restriction enzymes Nsp1 and Sty1(total 500ng DNA). 2) Ligation to adaptors. 
3) Generic primers recognizing the enzyme specific adaptor sequences amplify adaptor-ligated
DNA. 4) PCR purification with magnetic beads. 5) Fragmentation and labelling of  PCR products. 
6) Hybridization in the Affymetrix GeneChip® Hybridization Oven 640. 7) Wash and stain in the
Affymetrix GeneChip® Fluidics Station 450. 8)Array scan with the Affymetrix GeneChip® 
Scanner 3000 7G.
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RESULTS 
Early onset infantile-congenital-Rett syndrome (Paper I and III) 
In paper I, we studied all 14 clinically diagnosed early onset infantile RTT patients for 
aberration in MECP2 and CDKL5 genes. One of the patients had a pathogenic partial deletion 
including 2 exons of the MECP2 gene, detected by MLPA. Patient 2 in this study had a  
de novo  deletion of chromosome 3p, del(3)(pter→3p25.1~25.2), which was  detected and 
described in pervious studies.79,80 We suggest that the 3p deletion has more likely caused her 
phenotype, since we have not detected any pathogenic mutations in the MECP2 or CDKL5 
genes. In addition, the microarray analysis in our following study (paper III) confirmed that 
the 3p deletion is the only pathogenic CNV in her genome. This deletion contains 12 CNS 
expressed genes such as ATG7 and SLC6A1 which have showed relationship with mental 
retardation and epilepsy.79,80
We did not find any pathogenic mutation in the MECP2 or CDKL5 genes in other patients in 
this series (Table 2).  
Table 2 - Mutations analysis and microarray analysis results in early onset infantile 
Rett syndrome patients in summary: paper I and paper III  
Patient MECP2 CDKL5 FOXG1 CNV 
Mutation NV Mutation NV Type size 
1 ND ND ND ND - 
2 ND ND ND ND 11 Mb 
3 ND ND ND ND -
4 ND ND ND ND - 
5 ND ND ND ND 309 Kb 
6 ND c.[1035A>G (+) 1233C>T] ND ND - 
7 ND 992A>G ND ND - 
8 ND ND ND ND -
9 ND ND ND ND 102 Kb 
10 ND ND ND ND 191 Kb 
11 ND ND ND ND - 
12 ND ND ND ND - 
13 ND ND ND ND - 
14a          Del exon 1-2 ND - 
c.*131GA>AT 
c.*131GA>AT 
ND 
ND 
c.*131GA>AT 
ND 
c.*131GA>AT 
ND 
ND 
ND 
ND 
ND 
ND 
- - 
-
Distal 3p deletionb 
- 
- 
6q26 gainc  
- 
- 
- 
16p13.2 deletionc 
6q26 gainc 
- 
- 
- 
- - 
NOTE: NV = normal variant; ND = not detected; Del = deletion 
aCDKL5 analysis has not been performed for this patient since we identified a large deletion in MECP2, we
hypothesis that this deletion might cause her phenotype.
bdistal 3p deletion in pervious study by FISH.
cIntragenic CNV 
-
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Normal sequence variants (SNPs) were detected in 6 patients, 3 SNPs in the MECP2 (2 silent 
SNPs in patient 6 and another SNP in patient 7 inherited from her normal father). In CDKL5, 
we found the same intronic SNP in 4 patients. Angelman Syndrome was excluded for the 
cohort, by both clinical criteria and methylation analysis. In paper III, we began with 
mutation analysis for the FOXG1 gene in all 12 remaining patients from paper I (excluding 
patient 2 and patient 14) with DNA sequencing and we did not detect any pathogenic 
mutations in FOXG1 in the 12 patients. Then, we have further analysed the patients using 
affymetrix SNP6.0 array. We found 3 patients with variants of uncertain clinical significance 
(VOUS): two different duplications located on chromosome band  6q26 in the PARK2 gene, 
and a deletion at chromosome 16p13.2 in the RBFOX1 gene (Table 2). We also identified 
many regions with copy neutral Loss of Heterozygosity (LOH) in patient 4; including  
7q11.22-q22.1, 10p15.1-p15.3, 14q11.2-q13.3, 21q11.2-q21.1, Xp11.4-p22.33 and Xq23-q25. 
Severe mental retardation (paper II) 
The main objective of this study was to investigate the prevalence, co-morbidities and  
aetiologies of severe mental retardation in a cohort of 133 Swedish children (figure 5) and 
to further penetrate aetiologies in a group with unknown causes by application of updated  
clinical-genetic methods to estimate how todays methods as microarray  affects the rate of 
genetic diagnosis in this group. Assignation to SMR defined by IQ < 50 was based on 
psychological testing and/or careful evaluation of the cognitive developmental level (see also 
page 17). All children with Down syndrome were included.
Figure 5 Flow-chart showing the process of inclusion of aetiology categorization of SMR patients, and  
the number of patients in each group.
*The number of patients in “Unkown aetiology” decreased to 18 after SNP array analysis.
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 The prenatal unknown group included 23 children with indications of prenatal but  
unclassifiable aetiology. Although some of these patients had unspecific dysmorphic features, 
brain anomalies, epilepsy and additional dysfunctions, the clinical diagnosis were 
undetermined. The chromosome microarray method was implicated to find out if there are 
some pathogenic CNVs presented in this group, the aim was to investigate the impact of 
genetic methods choices on number of aetiologically diagnosed SMR patients. We identified 
pathogenic CNVs in 5/23 children, or 4/22, if the two brothers are calculated as one  
occurrence (a distal 10q deletion syndrome, a 5q14.3-q15  microdeletion  syndrome, a 22q11 
deletion syndrome and Xq28/MECP2 duplication syndrome in 2 brothers; Table 3).  
Table 3      Overview of detected pathogenic CNVs in prenatal unknown SMR patients 
by Cytogenetics Whole_Genome 2.7 M array and the Genome wide SNP6.0 
array (paper II)       
Sex Chr
 
Start 
position1(bp) 
End 
position1(bp) inheritance 
Loss 10q26.12-q26.3 122703669 133745133 12527 98  de novo 
Male 5 Loss 5q14.3 83132102 89994111 6862 17 de Novo 
Male   22 Loss 22q11.1-q11.21 17369300 19790008 2421 67 de Novo 
Male*   X Gain Xq28 152768158 153201808 433  18     Inherited (Mat) 
1UCSC Build 36 
ND: not determind
*Two brother s with same maternally inherited Xq28 duplication including MECP2 gene, the xq28/MECP2
duplication was detected by microarray analysis in one brother and the other brother was analysed using 
MECP2 specific MLPA assay. 
Mat: maternally
MECP2 duplication syndrome (paper IV) 
The all over aim of this study was to further investigate and compare the MECP2 duplication 
syndrome phenotype in female versus male patients. As the most of MECP2 duplication 
syndrome in male patients were inherited from healthy mothers, the duplication was 
considered as asymptomatic in females. The X chromosome inactivation (XCI) mechanism 
in female had been suggested to rescue the phenotype in carrier females. In paper IV; we 
identified a 101 kb tandem de novo MECP2 duplication, containing the MECP2 gene and 
exon 1-7 of the IRAK1 gene, in a female patient. XCI  status in leucocytes was random and she 
had slightly dysmorphic features which were in accordance with earlier reported phenotypes 
in affected females; high palate, pointed teeth and delayed developmental milestones.7  
The comparison between the SRO (shorter region of interest) in earlier reported cases in both 
gender and our cases in this study confirms that the MECP2 is the gene dosage sensitive gene 
(paper IV, figure 1). 
Female  10
Size (Kb) Locus
CNV 
type Genes
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The two brothers with MECP2 duplication syndrome (from prenatal unknown aetiology in 
study II) and their carrier mother and sister were also included in this study for further 
clinical observations. Although both the mother and sister were asymptomatic carrier the XCI 
pattern in blood was random for the mother and skewed (15:85) for the sister’s normal allele. 
However, the brothers showed different phenotype and responded to epilepsy treatment 
differently despite the same inherited (most likely identical) duplication. The younger brother 
died suddenly at 13 years age in coincidence with an unexpected response to respiratory 
infection.  
The results of this study underlines that the MECP2 duplications syndrome in males is more 
severe and may even lead to sudden death, this duplication in females has incomplete 
penetrance and variable expressivity, thus the symptoms might display milder and extend 
from asymptomatic to moderate MR. Female carrier status may be diagnostically important
as some symptoms, such as learning difficulties, are common for females with MECP2 
duplication syndrome.  
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________________________________________________________________ 
DISCUSSION 
In this thesis, we have undertaken extensive genetic analysis for the two groups of children 
with mental retardation. As discussed earlier the early infantile onset RTT patients have 
already had the clinical diagnosis and the main aim for this group was to find out the 
possible genetic variations associated to this diagnosis. The approach of genetic analysis of 
the other group (SMR with unknown aetiology) was the other way around; to identify a 
probable genetic variation as an implement for diagnosis. 
The findings in the unknown aetiology group were comprehensible with other available data 
and the interpretations of all four detected CNVs with microarray were easier since all of 
these findings were already described as syndromes (paper II). The clinical evaluation was 
affected by the lack of some symptoms in accordance with the syndromes, together with 
other additional symptoms in our patients, which directed the patients to the unknown 
aetiology group. Since this study is a based on epidemiologically collected material, one aim 
was to determine whether the prevalence of SMR in Scandinavia have changed compared to 
pervious studies, the hypothesis was that the implication of updated new diagnostic methods 
as well as the progress in genetic methodology may affect the number of diagnosed children 
with SMR. However, the outcome of this study implies that the aetiological prevalence of 
SMR is unchanged and is in accordance with those previously reported.12,13,81-83 In contrast, 
the high throughput microarray analysis elevated the rate of diagnosis from earlier 4 % to 
remarkable 22.5 % in unclear cases. At the initiation of the study in the year 2005, there were 
no coherent data supportive of association of CNVs with autism, which was why we 
excluded twenty-six children with autistic disorders without dysmorphic signs from the 
genetic analysis, these patients were classified as having undetermined aetiology. After that, 
many research groups have used a similar approach in autism studies and association of 
CNVs including both gains and losses has been reported.84-88 These results implies that 
microarray analysis in the excluded autistics group (n=26) might change our results 
somewhat and probably would have increased the number of detected pathogenic CNVs. 
On the other hand, we found various genetic abnormalities in the early infantile onset RTT 
patients. One explanation may be the phenotypic heterogeneity in this group, although all 
the girls included in this group full field the criteria that are required for classification of 
RTT variants, but within the group, the patients full field different criteria. Lack of MECP2 
aberration in the most of early infantile onset RTT variant patients (13/14 patients in paper I 
and III), motivated the microarray analysis approach. The MeCP2 protein has a repressor 
function, with many other proteins involved in the pathway. Mutation in these genes might 
lead to a phenotypic presentation similar to the phenotype of RTT. 
However, the microarray analysis results in this group include 3 different autosomal intra-
genic CNVs (2 in PARK2 and 1 in  RBFOX1). Although CNVs including both of these genes 
have showed association with autism and also other neurological disorders as schizophrenia, 
juvenile Parkinson disease and Alzimers disease. 70,87 However, these CNVs have uncertain 
significance and should be interpreted with caution since the CNVs are inherited from 
asymtomatic parents and are represented in the normal population (DVG database) as well. 
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Many factors have to be considered in these cases: 
Firstly, incomplete penetrance and variable expressivity for inherited CNVs, which have 
been reported for other microduplications/microdeletions syndromes as 22q11 
duplications syndrome. 
Secondly, the possibility of additional modifying factors as variations in combination, 
epigenetic factors or environmental elements may play the second-hit role in affected 
patients. 
Thirdly,  MECP2 mutations have also been reported in patients with other neurological 
disorders as autism and schizophrenia. This may implicate pathways with both MECP2 
and for example PARK2 gene.  
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________________________________________________________________ 
CONCLUSIONS 
In this thesis, we have analyzed early infantile onset “congenital” Rett syndrome variant 
patients with mutation analysis for candidate genes and further copy number variation 
analysis using SNP array. The children with SMR were epidemiologically investigated and 
categorised in our other study and the unknown aetiology group within the prenatal SMR 
group were analyzed with SNP array. The findings of our studies can be summarised as 
below: 
 The MECP2 gene aberrations may leads to earlier onst of Rett syndrome since we
found a MECP2 deletion in 1/14 early infantile onset RTT patients. Therefore,
we conclude that mutations screening of MECP2 should be recommended as the
first step in genetic analysis considering RTT variant patients.
 The causative genetic mechanisms of early infantile onset RTT is complex and may
be different as compared with classical Rett syndrome. This variant consists of a
phenotypically heterogeneous group of patients which has been reflected in genetic
heterogeneity; from mutations in candidate genes to CNVs. These results suggest
that copy number variant analysis with the microarray technique might be useful for
genetic analysis of this particular group as the second step in genetic analysis in
MECP2 negative patients.
 The prevalence and co-morbidity of severe mental retardation in Sweden is
unchanged and similar to previous Scandinavian studies (2.9 per 1000). The high- 
resolution chromosomal microarrays are valuable diagnostic tools of patients with
unexplained SMR and increased the number diagnosed patients from earlier 4%
(using traditional analysis methods) to todays 22.5%.
 MECP2 duplication is a pathogenic CNV in both genders with recurrence risk for 
both females and males; risk for recurrence is 50% for boys and less for girls because 
of incomplete penetrance. This has to be recognised in genetic counselling for 
carrier females. Follow up of carriers can be recommended because of the 
performance of late-onset neurological features in female carriers.
Medical relevance 
In conclusion, this thesis makes an effort to investigate the cause of two specific groups of 
patients with mental retardation. This follow up is essential for prognosis, management, 
and genetic counselling. 
Identification of underlying variations for MR has crucial implications for prevention and 
treatment. It is also important to provide inexpensive, accurate, and effective molecular 
analysis for families with mental retardation. The molecular diagnosis has major impact on 
the possibility to provide prognosis, correct treatment, and also to allow networking with 
patient organisations. Family studies might identify carriers of pathogenic variations and 
genetic counselling to determine risk of recurrence in future pregnancies.  
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________________________________________________________________
FUTURE PROSPECT 
Recent genetic studies in the field of mental retardation have contributed to progress of 
different areas from genetic counselling to treatment. The advent of new technologies as 
microarray in the last decade has been important for diagnostic methodology in MR. In the 
years to come, I believe research and genetic analysis concerning patients with SMR 
unknown aetiology and RTT variants will highly increase. Nowadays, families are more 
aware of the possibility to use genetic counselling and prenatal diagnosis becomes more and 
more included in the healthcare of pregnant women.  
For many years screening of the MECP2 gene for diagnostic proposes (for classical RTT) 
has been a well established method. Rett mouse models indicate an effective treatment 
strategy which suggesting new applications for possible human gene therapy. These results 
motivate us to further study RTT variants. Both the early infantile onset RTT variant and 
male patients with Rett-like features can contribute to find the disease causing genes, CNVs 
as well as other genetic elements. Exome sequencing analysis or whole genome sequencing 
analysis of these patients may identify other key elements. This combination of methods will 
provide an opportunity to find out both small and gross variations in the genome.  
The final goal will be to introduce the causative genetic vatiations for prenatal and screening 
of newborns. If this happens, it will be of assistance and improve the public healthcare 
system of service to patients and their families, and hopefully an aid to find an eventual cure 
(especially for the RTT patients).
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________________________________________________________________ 
POPULÄRVETENSKAPLIG SAMMANFATTNING  
Utvecklingsstörning definieras som ett tillstånd där en människas kognitiva förmåga inte 
utvecklats normalt. Det medicinska uttrycket för utvecklingsstörning är mental retardation 
(MR). Förekomsten av mental retardation är beräknad till 3 % i Europa. 
MR orsakas av genetiska förändringar hos individen i 25-35 % av alla fall, vilka antingen kan 
vara nedärvda från föräldrarna eller orsakas av nya förändringar i genomet, s.k. de novo 
mutationer. Därför är genetiska utredningar viktiga för att diagnostisera patienter med MR.  
Delarbetena i denna avhandling baseras på genetiska studier av två patientgrupper med MR.
Den första studien avser genetiska studier av barn med en variant av Rett syndrom (RTT) 
med tidig debut; ”early infantile onset Rett syndrome variant" (delarbete I och III). Rett 
syndrom är en neurologisk sjukdom som främst drabbar flickor med en incidens av 1:10 000. 
RTT kan förekomma hos pojkar men det är mycket ovanligt. 
Barnen med RTT utvecklas normalt initialt och symptomen uppträder efter 6-18  månader. 
Vid early infantile onset RTT har patienterna en diagnostisk debut före 6 månaders ålder 
vilket gör att de första månaderna av normal utveckling uteblir. RTT orsakas främst av 
genförändringar i MECP2, lokaliserad på X-kromosomen (Xq28). På  senare år har 
mutationer i två andra gener CDKL5 (Xp22) och FOXG1 (14q12) rapporterats i varianter av 
RTT. Därför har vi gjort en genetisk utredning av vår patientgrupp om 14 barn genom 
mutationsscreening av ovanstående 3 gener samt kompletterat med kopietalsanalys (Copy 
number variation, CNV). Kopietalsanalys är en relativt ny analysmetod som kan upptäcka 
betydligt mindre genetiska förändringar i arvsmassan på kromosomnivå, än en traditionell 
kromosomanalys. I delarbete I upptäckte vi en sjukdomsorsakande deletion (förlust av 
genetiskt material) i MECP2 genen hos en patient medan en annan patient uppvisade en stor 
deletion av den korta armen av kromosom 3. Vidareutredning med kopietalsanalys av 
resterande 12  patienter (delarbete III) visade tre olika CNVs. Två patienter hade en 
duplikation (extramaterial) på kromosomband 6q26 där PARK2 är lokaliserad, medan en 
patient hade deletion på kromosomband 16p13.2 i RBFOXG1. 
Dessa CNVs har föreslagits som potentiella sjukdomsorsakande avvikelser i litteraturen och 
kan inte uteslutas som bidragande orsak till patienternas symptom.
Delarbete II och IV i avhandlingen är en epidemiologisk studie av barn med svår mental 
retardation (SMR) och genetisk uppföljning av dessa. Denna studie genomfördes i samarbete 
med en barnneurolog i Hallands län där 133 barn med SMR identifierats. Patienterna är 
indelade i fyra kategorier i relation till beräknad tid för sjukdomens uppkomst; prenatal 
(innan födelse), perinatal (under förlossning), postnatal (efter födelse) eller vid obestämd 
debut. Den prenatala gruppen utgör den största andelen (82 patienter) varav 23 patienter är 
utan känd diagnos. Syftet med dessa studier var att undersöka den genomiska profilen hos 
dessa 23 patienter med hjälp av kopietalsanalys. Patogena CNVs upptäcktes hos 5 patienter i 
delarbete II och dessa är sedan tidigare beskrivna som kända syndrom: Distal 10q deletion 
syndrome, 5q14.3-q15 microdeletion syndrome samt 22q11deletion syndrome fanns hos 
vardera en patient medan Xq28/MECP2 duplication syndrome sågs hos två bröder. 
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I delarbete IV jämfördes sedan fenotypen mellan bröderna från arbete II med en 
kvinna med MECP2 duplikation för att se könsspecifika skillnader.	   
ÖVERGRIPANDE SLUTSATSER: 
 En patient med early onset infantile Rett syndrom med deletion i MECP2
visar att förändringar av MECP2 kan ge upphov till en mycket tidigare
sjukdomsdebut än tidigare känt.
Kopietalsanalys (SNP array) är ett effektivt genetiskt analysredskap för
diagnostisering av mental retardation. Metoden har lett till en ökning av
antalet diagnostiserade SMR patienter, från 4 % till 22,5 %.
MECP2 duplikation är sjukdomsorsakande med 50 % upprepningsrisk
för män och något lägre för kvinnor, vilket bör beaktas vid genetisk
vägledning.


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"Just as opportunities also contains problems, 
every problem brings an opportunity."
DAN MILLMAN 
”The life you were born to live”
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